Money Makers Mentor

Taysha Gene Therapies Closes $95 Million in Series B Financing

Taysha Gene Therapies, a patient-focused gene therapy company, recently closed $95 million in series B financing. The company’s financing comes from a range of life science investors led by Fidelity Management and Research Company LLC. The company’s primary objective is to eradicate Central Nervous System (CNS) disease.

CNS disease describes a wide range of conditions effecting the brain’s ability to function. Proceeds from the series B financing round will aid Taysha’s ultimate goal. The money will advance clinical programs, speed up the process on new medications, and build a GMP manufacturing facility. In partnership with the UT Southwestern Gene Therapy program, the company also plans to continue developing its own portfolio.

READ MORE: Permira Portfolio Company Announces Dev…

Leave A Reply

Your email address will not be published.